HOUSTON / Mar 03, 2025 / Business Wire / U.S. Physical Therapy, Inc. (the Company”) (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced the acquisition of a physical therapy practice with three clinic locations in Wyoming, which currently generates approximately $4.3 million in annual revenues and 23,000 in annual visits. The Company acquired a 65% interest in the acquired company with the current owners retaining a 35% ownership interest.
Graham Reeve, Chief Operating Officer-West, said, “We are excited to welcome our newest partners into our USPH family and expand our service offerings in the state of Wyoming. This team has developed incredible relationships in the communities they serve, and we look forward to assisting and supporting them as they continue to build on this foundation in the future.”
About U.S. Physical Therapy, Inc.
Founded in 1990, U.S. Physical Therapy, Inc. owns and/or manages 775 outpatient physical therapy clinics in 43 states. USPH clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. USPH also has an industrial injury prevention business which provides onsite services for clients’ employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.
More information about U.S. Physical Therapy, Inc. is available at www.usph.com. The information included on that website is not incorporated into this press release.
| Last Trade: | US$77.86 |
| Daily Change: | -0.90 -1.14 |
| Daily Volume: | 233,380 |
| Market Cap: | US$1.180B |
November 05, 2025 August 06, 2025 August 01, 2025 April 30, 2025 | |

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load